Antiretroviral therapy, cancer prevention and care in Africa The experience of the IeDEA West Africa Collaboration Pr Francois Dabis and Dr Antoine Jaquet.

Slides:



Advertisements
Similar presentations
Overview of HIV/AIDS Care and Treatment Country Situation & KATH Lambert T. Appiah Lambert T. Appiah.
Advertisements

CD4-specific rates of death and tuberculosis among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.
HIV and cancer in referral hospitals from four West African countries The IeDEA West Africa Collaboration A Jaquet, M Odutola, DK Ekouevi, A Tanon, E Oga,
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
Brazzaville, Congo 5-7 March 2014
Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,
Early Infant Diagnosis: Challenges and Solutions A special session IAS, Vienna 2010.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Assessment of PEPFAR’s Impact on Selected Health System Parameters in Sub-Saharan African Countries Presented by: Anya Shen Viviane D. Lima, Wendy Zhang,
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Linda-Gail Bekker The implementation of this project was made possible.
Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
The National Cancer Intelligence Network An overview Professor David Forman Professor of Cancer Epidemiology, University of Leeds NCIN – Lead for Information.
Moving to the final chapter of the AIDS epidemic.
Module 1: Final Case Study #1-CS-1. Case Study: Instructions v Try this case study individually. v We’ll discuss the answers in class. # 1-CS-2.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Cervical Cancer and HIV: Interactions and Interventions Jean R. Anderson, M.D. Jhpiego, an affiliate of Johns Hopkins University The Johns Hopkins University.
Disclosure of HIV test results in HIV-infected adolescents in the Aconda program (CePReF, CHU Yopougon) in Abidjan, Côte d’Ivoire: The Project PRADO-CI.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
Quality Management Update March 18, New Performance Improvement Project (1) Title: Controlled Substance Prescription Monitoring Program Database.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.
Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,
1 Lecture 20: Non-experimental studies of interventions Describe the levels of evaluation (structure, process, outcome) and give examples of measures of.
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
Unit 1: Overview of HIV/AIDS Case Reporting #6-0-1.
Effectiveness of Micronutrient-rich Lipid Nutrient Supplements in Delaying Clinical Progression of HIV in Malawian Adults Heidi Sandige, MD.
HIV/AIDS in Africa All charts/diagrams/graphs taken from UNAIDS websiteUNAIDS website
NIH U-01 Application Limited Competition: Women’s Interagency HIV Study (WIHS-V)
ICAP Quarterly Master Slide Set April-June Site Census What: Ongoing, real-time inventory of all planned, current, and closed ICAP sites. Supported.
Our vision: Healthier communities, Excellence in healthcare Our values: Teamwork, Honesty, Respect, Ethical, Excellence, Caring, Commitment, Courage DOTS.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
Bi-national Commission for Collaboration on Health Guyana and Suriname. Presenter Mr. Nicholas Persaud –National HIV Care and Treatment Coordinator. Guyana.
"Protecting the Unborn Child" European Parliament Policy Debate 7 th September 2011, Brussels Measuring the problem of alcohol and the unborn child Dr.
European HIV/AIDS programmes: EDCTP as a model of Europe-Africa partnership 19 July 2011 IAS 2011 Rome, Italy Charles S Mgone EDCTP Executive Director.
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Integrating PMTCT and ART N. Shaffer PMTCT/Peds TWG PEPFAR Track 1 Sept 25, 2007.
Scaling up HIV Paediatric care Harvard – PEPFAR Program Chalamilla Guerino
Unit 6: Second-Generation HIV/AIDS Surveillance #1-6-1.
Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.
Lessons from the CDC/RTC HIV Integration Project Marianne Zotti, DrPH, MS, FAAN Team Leader Services Management, Research & Translation Team NCCDPHP/DRH/ASB.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Co-infections TB/HIV in prison Côte d’Ivoire Case study Doctor J-M MASUMBUKO ESTHER Coordinator in Côte d’ivoire 24 July th IAC,
National Strategy for Quality Improvement in Health Care June 15, 2011 Kana Enomoto Director Office of Policy, Planning, and Innovation.
Cancer Day February 4 th,2010 National Cancer Strategies By Dr. Asad Ramlawi D.G.PHC & PH.
Use of Routine Feedback Reports to Site and District Staff in Cote d’Ivoire Hermann Brou Annual Meeting, M&E satellite meeting Johannesburg, July 28, 2010.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Georgia Comprehensive Cancer Control Program 3/10/2015 Program Monitoring and Evaluation Activities Short-Term Outcomes Long-Term Outcomes Intermediate.
PMTCT - The Platform for integrating HIV/AIDS Services in the MCH Clinic. Bola Oyeledun, MD, MPH Track 1.0 Partners Meeting Washington DC. August 2008.
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
United Republic of Tanzania Ministry of Health & Social Welfare MINISTRY OF HEALTH AND SOCIAL WELFARE NATIONAL AIDS CONTROL PROGRAM HIV CARE AND TREATMENT.
Department of Preventive Medicine Faculty of Public Health University of Debrecen General Practitioners’ Morbidity Sentinel Stations Program (GPMSSP) to.
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults B. Tchakounte Youngui1, P. Coffie2, E. Messou3,
Capacity to screen and treat mental health and substance use disorders at HIV treatment sites in low- and middle-income countries Angela Parcesepe1,2,
Non-Communicable Diseases Risk Factors Survey in Georgia
Using HIV cohort collaboration data to evaluate and inform policy and practice Mary-Ann Davies.
World Health Organization
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Assessment of risk factors for hepatocellular carcinoma in HIV care and treatment programs across 31 countries: a cross-sectional survey within IeDEA C.
Presentation transcript:

Antiretroviral therapy, cancer prevention and care in Africa The experience of the IeDEA West Africa Collaboration Pr Francois Dabis and Dr Antoine Jaquet Institute of Public Health, Epidemiology & Development (ISPED), Bordeaux University

2 IeDEA International Epidemiologic Databases to Evaluate AIDS International research consortium established in 2005 by the US National Institute of Allergy and Infectious Diseases (NIH) Resource for globally diverse HIV/AIDS data To address research questions in HIV/AIDS unanswerable by single cohorts First round ; Second round : currently year 9: July 2014 to June 2015

3 IeDEA Regions

4 WADA: 17 adult and 11 pediatric centres in 10 countries Benin, Burkina Faso, Côte d’Ivoire, Ghana, Guinea, Guinea-Bissau, Mali, Nigeria, Senegal, Togo Coordinating Center: ISPED, Univ Bordeaux, France Regional Office: PAC-CI, CHU Treichville, Abidjan Côte d’Ivoire IeDEA West Africa (WADA)

5 WADA Objectives (1) To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes

6 WADA Objectives (2) To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes To increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children

7 WADA Objectives (3) To measure the effectiveness of ART in HIV-infected individuals in West Africa in the long-term, and to assess factors that influence program and treatment outcomes To increase the capacity for delivering ART durably in West Africa by increasing the capacity for monitoring clinical outcomes at the individual and population levels in adults and children To document the morbidity burden in HIV-infected individuals in care in HIV programs throughout West Africa to look for prevention and care solutions

8 WADA study design Observational prospective multi-center cohort Pooled database of HIV-infected adults and children data followed in reference clinics in West Africa Additional surveys to address specific questions / specific populations With a focus on cancer in people living with HIV

9 Current WADA merger Retrospective and prospective cohort HIV-infected adults on ART N= 59,941 HIV-2 or (HIV-2 and HIV-1) positive N= 4,818 HIV-exposed children N= 2,819 HIV-infected children without ART N= 1,775 HIV-infected children with ART N= 4,899

Context How routinely collected data can help addressing priority research questions in the area of HIV-related malignancies in West Africa? – No routine data collection on cancer and its risks factors available among HIV-infected patients – Sparse functional cancer registries – No national death registries and no national identification number Need to document HIV-related malignancies and their risk factors in West Africa using appropriate approaches 10

Studying cancer risk factors Dedicated prevalence studies in WADA participating clinics Alcohol and tobacco use in HIV-infected patients Jaquet et al. Int J Tub Lung Dis, 2009 Jaquet et al. Addiction, 2010 – Documented the diversity of substance abuse across different countries using standardized & reproducible tools – Perspectives Enables the extension of this approach In other IeDEA regions Over time in the same sites to identify trends Minimal data collection for clinical use? 11

HIV-related malignancies (1) Cancer of the cervix & precancerous lesions – Cancer of the cervix sufficiently frequent and eligible to an affordable preventive approach including screening and early treatment – Operational characteristics related to the screening in HIV-positive women were documented (Horo et al. BMC Public Health 2012) – Factors associated with precancerous lesions among ART-treated HIV- positive women were investigated (Jaquet et al. Plos One 2014) – Perspectives Follow-up of initially screened women to assess the incidence of new lesions as well as recurrent lesions in previously treated women Integration in routine HIV care? 12

HIV-related malignancies (2) How to document less common HIV-related malignancies? Extend the WADA network to cancer referral centers HIV and cancer in referral hospitals from four West African countries – Systematic collection of HIV status in patients with a malignant condition attending clinical wards from participating referral hospitals – Allowed the comparison of HIV seroprevalence in selected cancers known or suspected to be linked to HIV to a referent group of patients with malignant conditions unrelated to HIV – To be presented in the following session “Beyond Control of HIV: Comorbidities and Coinfections around the World” on Wednesday 16:30 (Melbourne Room 1) 13

Conclusions The WADA network allowed the collection of various cancer risk factors and precancerous conditions amenable to prevention strategies in West Africa – Particularly important in a context of unaffordable therapeutic approach for cancer with advances stages Limitations – Unable to collect reliable and detailed information of invasive malignancies in HIV cohorts as morbid events Perspective – Initiate prospective sub-cohorts of “high-risk populations” within the WADA collaboration focusing on selected types of cancers Ex: “Hepatocarcinoma among HIV/HBV co-infected cohorts” 14

Acknowledgments All patients & medical staff that participated to the cancer studies HIV & Cancer studies coordinators & investigators Bordeaux: E Balestre, A Sasco Benin: J Akakpo, J Sehonou, DM Zannou Côte d’Ivoire: A Tanon, A. Attia, SP Eholie, E. Bissagnene Nigeria: E Oga, M Odutola, E Jedy-Agba, M Charurat, C Adebamowo Togo: DK Ekouevi, B Goilibe PACCI regional center for data management : TA Azani, P Coffie & colleagues WADA PIs: E Bissagnene & F Dabis